Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa

PURPOSE: Anaplastic lymphoma kinase (ALK) gene alterations are potent oncogenic drivers in non–small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting the ALK pathway are effective in treating ALK-positive NSCLC. Around 5% of Asian and White patients with NSCLC have ALK-positive tumors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazieh, Abdul Rahman, Gaafar, Rabab, Errihani, Hassan, Jaafar, Hassan, Al Dayel, Fouad, Bahnassy, Abeer A., El Kadi, Hatem, Abdallah, Mohamed Magdy, Zaatari, Ghazi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613346/
https://www.ncbi.nlm.nih.gov/pubmed/34788123
http://dx.doi.org/10.1200/GO.21.00067

Ejemplares similares

Ejemplares similares